Pacific Biosciences Of California (PACB) Short-term Investments (2010 - 2026)

Pacific Biosciences Of California has reported Short-term Investments for 17 years, with the latest figure at $219.7 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 22.81% year-over-year to $219.7 million; the trailing twelve-month figure through Mar 2026 stood at $219.7 million (down 22.81% YoY), and the FY2025 full-year result was $215.8 million, down 35.5% from the prior year.
• Short-term Investments for Q1 2026 stood at $219.7 million, up from $215.8 million in the prior quarter.
• The five-year high for Short-term Investments was $620.6 million in Q2 2023, with the low at $300000.0 in Q3 2022.
• Average Short-term Investments over 5 years is $260.4 million, with a median of $242.2 million recorded in 2025.
• Year-over-year, Short-term Investments surged 196135.33% in 2022 and tumbled 99.94% in 2024.
• Tracing PACB's Short-term Investments over 5 years: stood at $447.2 million in 2022, then climbed by 0.96% to $451.5 million in 2023, then declined by 25.9% to $334.6 million in 2024, then plunged by 35.5% to $215.8 million in 2025, then advanced by 1.8% to $219.7 million in 2026.
• The last three Short-term Investments figures came in at $219.7 million (Q1 2026), $215.8 million (Q4 2025), and $242.2 million (Q3 2025), per Business Quant data.

Peer Comparison